Wockhardt to exit US generic pharma segment to unlock capital for high-impact areas

Wockhardt Ltd on July 11 said it has decided to exit US generic pharmaceutical segment to unlock capital for high-impact areas.

"Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio," said the company in a stock exchange filing.

"This strategic reset aligns with Wockhardt’s sharpened focus on building a future-ready business anchored in two key pillars:
1. New Antibiotic Drug Discovery – where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets.
2. Biologicals Portfolio in Insulin – leveraging advanced technologies to address critical unmet needs in diabetes care," the company added.

Wockhardt said its US generics business has been incurring losses over the past several years. In FY 2025 alone, the generics business incurred a loss of nearly $8 million, it said.